JAK Inhibitors

At the moment we have been given a new therapeutic option for patients who do not respond to TNF inhibitors - Przemyslaw J. Kotyla

JAK Inhibitors

image by: BJC Health - Connected Care

HWN Recommends

The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors

Since the end of the last century, biological therapies have taken the rheumatoid arthritis (RA) pharmaceutical market by storm. Anti-TNFs were launched in the late 1990’s and have rapidly become worldwide brands. Within a decade, Humira was the highest earning product across the entire market.

The success of biologics was defined by their comparable high efficacy over traditional therapeutic agents. This was primarily driven by advances in specific target selectivity. Older treatments such as methotrexate and corticosteroids are comparatively blunt tools, with a myriad of effects across the immune system and dose limiting toxicity. Treatment with biologics has led to a seismic shift…

read full article


Related Articles

Stay Connected

©2022 | HealthWorldNet, Inc. | 114784

Last Updated : Thursday, November 17, 2022